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chestjournal.orgBACKGROUND: Cardiovascular disease is a frequent comorbidity in patients with COPD.
Many physicians, particularly pulmonologists, are reluctant to use b-adrenoceptor blocking
agents (b-blockers) in patients with COPD, despite their proven effectiveness in preventing
cardiovascular events.
METHODS: The large (5,162 patients) phase III TONADO 1 and 2 studies assessed lung
function and patient-reported outcomes in patients with moderate to very severe COPD
receiving long-acting bronchodilator treatment across 1 year. This post hoc analysis char-
acterized lung-function changes, patient-reported outcomes, and safety in the subgroup of
patients receiving b-blockers in the studies.
RESULTS: In total, 557 of 5,162 patients (11%) received b-blockers at baseline. Post-
bronchodilator FEV1 at baseline was higher in the b-blocker group (1.470 L) compared with
that in the no b-blocker group (1.362 L). As expected, patients receiving b-blockers had a
more frequent history of cardiovascular comorbidities and medications. Lung function
improved from baseline in patients with or those without b-blocker treatment, and no
relevant between-group differences were observed in trough FEV1 or trough FVC at 24 or
52 weeks. No relevant differences were observed for St. George’s Respiratory Questionnaire
results and Transition Dyspnea Index in patients with b-blockers compared with those in
patients without. Safety ﬁndings were comparable between groups.
CONCLUSIONS: Lung function, overall respiratory status, and safety of tiotropium/olodaterol
were not inﬂuenced by baseline b-blocker treatment in patients with moderate to very severe
COPD. Results from this large patient cohort support the cautious and appropriate use of
b-blockers in patients with COPD and cardiovascular comorbidity.
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Cardiovascular disease is linked closely with COPD,
mainly because of, but not limited to, the shared risk of
smoking.1,2 Cardiac failure is a leading cause of death in
patients with COPD.3 Physicians often are reluctant to
use b-blockers in patients with COPD because of a fear
that their use leads to deterioration in lung function2 or
that the effectiveness of COPD medications—
speciﬁcally, inhaled b-agonists—may be reduced. This
concern is reﬂected by their underuse, with limited
prescription of b-blockers2,4 and low daily dosage in
patients with COPD.
As a drug class, b-agonists have the potential to be
associated with cardiovascular adverse events (AEs) in
obstructive lung disease.5-7 Even though the risk-beneﬁt
proﬁles of b-agonists, including olodaterol,8 are well
established,6,9 there is no strict guidance for their use in
patients with very severe cardiovascular disorders who
may beneﬁt from b-blocker treatment. Consequently, it
has been advised that b-agonists are to be used with
caution in patients with pulmonary disease or severe
cardiovascular disease and who are taking b-blockers.6,10
Both cardioselective and noncardioselective b-blockers
have been reported to worsen pulmonary function in
patients with concomitant heart failure and COPD,11,12
and cardioselective b-blockers worsen dynamic
hyperinﬂation during cycling exercise in patients with
stable COPD.13 There may be some reluctance among
physicians to continue b-blockers during an episode of
acute COPD exacerbation, perceiving the patients’FUNDING/SUPPORT: This work was supported by Boehringer Ingel-
heim Pharma GmbH & Co. KG. Medical writing assistance was con-
tracted and compensated by Boehringer Ingelheim Pharma GmbH &
Co. KG.
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1316 Original Researchrespiratory condition as more delicate.14 In contrast,
administrative database studies suggest that b-blocker
use is associated with a 30% reduction in COPD
exacerbation rate and even may reduce mortality in
patients with COPD.15-17 A large prospective follow-up
study in the COPDGene cohort provided evidence that
b-blockers have an acceptable safety proﬁle in patients
with Global Initiative for Chronic Obstructive Lung
Disease (GOLD) II through IV COPD, including those
with severe COPD using home oxygen, and are
associated with fewer exacerbations in this population.18
This issue is important because a large number of
patients with COPD theoretically could beneﬁt from
b-blocker use, including patients with cardiac
comorbidities such as heart failure, coronary artery
disease, and hypertension.19
The TONADO studies established the efﬁcacy and safety
of once-daily maintenance treatment with the
combination of tiotropium/olodaterol in patients with
moderate to very severe COPD (GOLD II-IV).20 Overall,
approximately 10% of the 5,162 patients in the
TONADO studies were receiving b-blockers, providing
a unique opportunity to study their impact on lung
function, quality of life, and AEs in a large cohort of
patients across 1 year. This post hoc analysis was
designed to compare lung function, quality of life,
dyspnea, and frequency of COPD exacerbations in
patients with COPD according to baseline b-blocker use
in the TONADO studies.Materials and Methods
Study Design
The study design of the TONADO research program, which comprised
multinational, replicate, phase III, multicenter, randomized, double-
blind, active-controlled, ﬁve-arm, parallel-group studies (study
1237.5, NCT01431274; study 1237.6, NCT01431287) has been
published previously.20 Randomization details are summarized in
e-Appendix 1. Data combined from all treatment arms were used for
this cohort study. Baseline b-blocker use was a surrogate for usethroughout the study duration; patients who received b-blockers at
baseline were allowed, and expected, to continue with this treatment
for the duration of the 1-year study.
Patients
Inclusion and exclusion criteria of the TONADO studies have been
published previously20 and are summarized in e-Appendix 1. Both
studies were performed in accordance with the Declaration of
Helsinki, the International Conference on Harmonisation’s
Harmonised Tripartite Guideline for Good Clinical Practice, and
local regulations. Details of institutional review board approval are
provided in e-Appendix 1.
End Points and Assessments
The end points for lung functionwere trough FEV1 response (change from
baseline) andFVCresponse at 24and52weeks. Patient-reportedoutcomes
evaluated were St. George’s Respiratory Questionnaire (SGRQ) total score
and Transition Dyspnea Index score at 24 and 52 weeks.
Further safety end points were investigator-reported AEs (AEs, serious
AEs, fatal AEs, AEs leading to discontinuation, and most frequent AEs
according to system organ class) and frequency of COPD
exacerbations. Moderate exacerbations were those requiring
antibiotics or systemic steroids without hospitalization, and severe
exacerbations were those requiring hospitalization.[ 1 5 3 # 6 CHES T J U N E 2 0 1 8 ]
Statistical Analysis
To compare patients with and those without b-blockers and to take
into account potential confounding variables, we adapted the model
used for treatment comparisons in the TONADO studies and
adjusted it for additional variables. The adjusted means (SEs) for the
efﬁcacy comparisons were obtained from ﬁtting a mixed-effects
model for repeated measures, with further information provided in
e-Appendix 1. Time to ﬁrst exacerbation is presented for the ﬁrst
quartile (ie, the time at which 25% of patients reached this end705 (1
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89 (16.0%) discontinued study medication:
       61 (11.0%) AEs
       4 (0.7%) noncompliant
       0 (0.0%) lost to follow-up
       24 (4.3%) consent withdrawn
       0 (0.0%) other reason
5,163 randomized to
tiotropium, olodaterol,
tiotropium/olodatero
1,724 not randomized
6,887 screened
Completed
468 (84.0%)
Patients receiving
β-blockers
Treated set
n = 557
Figure 1 – Consolidated Standards of Reporting Trials diagram by baseline
AE ¼ adverse event.
chestjournal.orgpoint) using Kaplan-Meier estimates of probability of COPD
exacerbation across the 1-year study. Hazard ratios between patients
with and those without b-blockers were estimated using a Cox
proportional hazards model adjusting for the same additional
variables as the mixed-effects model for repeated measures. Analyses
of AEs were descriptive and not adjusted for potential confounding
variables. All P values and comparisons presented are nominal
because this is a post hoc analysis, and no adjustment for
multiplicity has been performed.Results
In total, 5,163 patients (2,624 from study 1237.5 and
2,539 from study 1237.6) were randomly assigned to
receive treatment; all patients were treated, except one in
study 1237.6 (Fig 1). At study entry, 557 patients were
treated with b-blockers, and 4,605 were not, with 468
(84.0%) and 3,900 (84.7%) patients, respectively,
completing the studies. Cardioselective b-blockers were
used by at least 80% of b-blocker users (e-Table 1).
Baseline patient characteristics between groups were
generally well balanced (Table 1). Patients in the
b-blocker group had less severe COPD and higher mean
baseline postbronchodilator FEV1, which also was
reﬂected in a higher number of patients with GOLD IICOPD and fewer patients with GOLD III or IV COPD
than in the no b-blocker group. Change in
prebronchodilator to postbronchodilator FEV1 was
consistent in patients with and those without b-blockers
at 162 and 172 mL, indicating no inﬂuence of b-blockers
on short-term bronchodilator reversibility. A similar
proportion of patients in each group had received
pulmonary medications before the study. More patients
took lipid-modifying drugs and angiotensin-converting
enzyme inhibitors in the b-blocker group than in the
no b-blocker group. Most patients (99%) also took
b-blockers during the study. More patients in the
b-blocker group had a history of myocardial infarction,
cerebrovascular accidents, and cardiac arrhythmia than
did those in the no b-blocker group (Table 2).5.3%) discontinued study medication:
0 (8.3%) AEs
 (1.1%) noncompliant
 (0.6%) lost to follow-up
4 (4.6%) consent withdrawn
 (0.8%) other reason
 or
l
1 patient not treated
Completed
3,900 (84.7%)
Patients not receiving
β-blockers
Treated set
n = 4,605
b-blocker, including discontinuations and causes, for combined studies.
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TABLE 1 ] Demographic and Baseline Patient Characteristics (Treated Population): Combined Data (N ¼ 5,162)
Characteristic b-Blocker (n ¼ 557) No b-Blocker (n ¼ 4,605)
Male, No. (%) 393 (70.6) 3,369 (73.2)
Age, mean (SD), y 65.0 (7.7) 63.9 (8.4)
Smoking status, No. (%)
Exsmoker 359 (64.5) 2,895 (62.9)
Current smoker 198 (35.5) 1,710 (37.1)
BMI, mean (SD), kg/m2 28.5 (5.6) 25.5 (5.4)
Exacerbations in the y before study entry, No. (%) 220 (39.5) 1,976 (42.9)a
No. of exacerbations, mean 0.7 0.8
Prebronchodilator screening FEV1, mean (SD), L 1.308 (0.502) 1.190 (0.491)
Postbronchodilator screening FEV1, mean (SD), L 1.470 (0.504) 1.362 (0.510)
Change from prebronchodilator to
postbronchodilator FEV1, mean (SD), L
0.162 (0.143) 0.172 (0.145)
FEV1/FVC, mean (SD), % 49 (11) 45 (12)
% predicted normal FEV1, mean (SD) 53 (14) 50 (15)
GOLD, No. (%)b
I ($ 80%) 0 (0.0) 3 (0.1)
II (50% to < 80%) 330 (59.2) 2,258 (49.0)
III (30% to < 50%) 191 (34.3) 1,798 (39.0)
IV (< 30%) 36 (6.5) 545 (11.8)
Baseline pulmonary medication, No. (%)
SAMAc 89 (16.0) 576 (12.5)
LAMAd 217 (39.0) 1,623 (35.2)
SABAe 230 (41.3) 1,849 (40.2)
LABAf 276 (49.6) 2,117 (46.0)
ICSg 241 (43.3) 2,205 (47.9)
Xanthinesh 52 (9.3) 464 (10.1)
Baseline cardiovascular medication, No. (%)i
Lipid-modifying drugs 276 (49.6) 771 (16.7)
ACE inhibitors 163 (29.3) 556 (12.1)
ACE inhibitor combinations 39 (7.0) 125 (2.7)
Angiotensin II antagonist combinations 40 (7.2) 155 (3.4)
Angiotensin II antagonists 84 (15.1) 369 (8.0)
Cardiac glycosides 14 (2.5) 25 (0.5)
Cardiac stimulants excluding cardiac glycosides 3 (0.5) 22 (0.5)
ACE ¼ angiotensin-converting enzyme; GOLD ¼ Global Initiative for Chronic Obstructive Lung Disease; ICS ¼ inhaled corticosteroid; LABA ¼ long-acting
b2-agonist; LAMA ¼ long-acting muscarinic antagonist; SABA ¼ short-acting b-agonist; SAMA ¼ short-acting muscarinic antagonist.
aThree patients had missing values.
bBased on postbronchodilator FEV1 % predicted (in study 1237.6, one patient receiving tiotropium 2.5 mg was not categorized).
cIpratropium, ipratropium with fenoterol or ipratropium with salbutamol, and oxitropium.
dTiotropium.
eSalbutamol, fenoterol, ipratropium with fenoterol, and ipratropium with salbutamol.
fIncluding salmeterol, formoterol, indacaterol, salmeterol with ﬂuticasone, formoterol with budesonide, and formoterol with beclomethasone.
gIncluding beclomethasone, budesonide, ciclesonide, ﬂuticasone, mometasone, salmeterol with ﬂuticasone, formoterol with budesonide, formoterol with
beclomethasone, and formoterol with mometasone.
hIncluding aminophylline and theophylline. Total number of patients includes only those with values for b-blocker use at baseline.
iCombination therapies are listed under each monotherapy drug class.Lung Function
Adjusted mean trough FEV1 responses at 24 weeks were
similar in both the b-blocker and no b-blocker groups,1318 Original Researchwith a between-group difference of 0.010 L
(95% CI, 0.009 to 0.028) (Table 3). Similarly, the
adjusted mean trough FVC responses were not modiﬁed[ 1 5 3 # 6 CHES T J U N E 2 0 1 8 ]
TABLE 2 ] Preexisting Disease Diagnoses by b-Blocker
Use
Diagnosis, No. (%)
b-Blocker
(n ¼ 557)
No b-Blocker
(n ¼ 4,605)
Cardiac disorders 289 (51.9) 818 (17.8)
Coronary artery
disease
99 (17.8) 190 (4.1)
Myocardial infarction 55 (9.9) 78 (1.7)
Angina pectoris 40 (7.2) 66 (1.4)
Myocardial ischemia 39 (7.0) 88 (1.9)
Cardiac arrhythmia 84 (15.1) 211 (4.6)
Vascular disorders 487 (87.4) 1,994 (43.3)
Hypertension 468 (84.0) 1,789 (38.8)
Cerebrovascular
accidents
41 (7.4) 126 (2.7)
Transient ischemic
attack
22 (3.9) 68 (1.5)
Stroke 22 (3.9) 66 (1.4)
Heart failure NYHA
class III or IV
12 (2.2) 20 (0.4)
Prostatic hyperplasia
or bladder neck
obstruction
56 (10.1) 409 (8.9)
Renal or urinary
tract diseases
43 (7.7) 225 (4.9)
Narrow-angle glaucoma 7 (1.3) 16 (0.3)
Cancer 43 (7.7) 190 (4.1)
NYHA ¼ New York Heart Association.signiﬁcantly by b-blocker use, with a between-group
difference of 0.010 L (95% CI, 0.048 to 0.028). At
52 weeks, the differences between the b-blocker and no
b-blocker groups for trough FEV1 and FVC responses
were also similar (0.005 L and 0.008 L, respectively).
Symptom Beneﬁt
There was no difference in baseline mean SGRQ total
score between the b-blocker and no b-blocker groups.TABLE 3 ] Adjusted Mean (SE) Trough FEV1 and Trough FV
Weeks of Treatment by b-Blocker Use at Baselin
Response
b-Block
(n ¼ 55
24 wk
Trough FEV1 response, adjusted mean (SE), L 0.080 (0.
Trough FVC response, adjusted mean (SE), L 0.140 (0.
52 wk
Trough FEV1 response, adjusted mean (SE), L 0.044 (0.
Trough FVC response, adjusted mean (SE), L 0.111 (0.
Data obtained from ﬁtting a mixed-effects model for repeated measures, incl
interaction, baseline, and baseline-by-test-day interaction; patient as a rand
and Kenward-Roger approximation of denominator degrees of freedom.
chestjournal.orgAfter 24 weeks, there was a greater, signiﬁcant reduction
(improvement) in adjusted mean SGRQ total score in
the b-blocker group compared with that in the no
b-blocker group (treatment difference, 1.39;
95% CI, 2.581 to 0.207) (Table 4). This treatment
difference decreased to 0.60 (95% CI, 1.810 to 0.602)
at 52 weeks. Dyspnea improved from baseline after 24
and 52 weeks in both groups (Table 4). Only small,
nonsigniﬁcant differences in improvement in Transition
Dyspnea Index were observed in the b-blocker group
compared with those in the no b-blocker group (0.18;
95% CI, 0.469 to 0.115 and 0.13; 95% CI, 0.424 to
0.170 at 24 and 52 weeks, respectively).
Safety
After 52 weeks of treatment, the proportion of patients
with an AE was similar in both groups (Table 5), as was
the proportion with speciﬁc AEs with an incidence
> 2%. Respiratory AEs, speciﬁcally COPD, occurred at a
slightly higher frequency in the no b-blocker group. In
the b-blocker group, 19.4% experienced a serious AE
compared with 16.0% in the no b-blocker group. The
most frequent class of serious AEs in the b-blocker
group was respiratory, thoracic, and mediastinal
disorders (5.4% compared with 7.2% in the no b-blocker
group), followed by infections and infestations
(3.6% compared with 2.8%), cardiac disorders
(3.2% compared with 1.6%), and neoplasms
(2.9% compared with 2.1%) (Table 5).
Incidence of fatal AEs was low across both groups:
2.0% in the b-blocker group and 1.4% in the no
b-blocker group (Table 5). The most frequent class of
fatal AEs in both groups was cardiac disorders
(1.1% compared with 0.3% in the no b-blocker group).
Incidence of major adverse cardiovascular events was
low, with 2.7% in the b-blocker group and 2.0% in the
no b-blocker group (data not shown).C Responses (Change From Baseline) After 24 and 52
e (Full Analysis Set): Combined Data
er
7)
No b-Blocker
(n ¼ 4,605)
Treatment Difference
(95% CI), L
009) 0.070 (0.003) 0.010 (0.009 to 0.028)
018) 0.150 (0.006) 0.010 (0.048 to 0.028)
009) 0.049 (0.003) 0.005 (0.024 to 0.014)
018) 0.119 (0.006) 0.008 (0.047 to 0.030)
uding ﬁxed effects of treatment, planned test day, treatment-by-test-day
om effect; spatial power covariance structure for within-patient errors;
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TABLE 4 ] Adjusted Mean (SE) SGRQ Total Score and TDI Focal Score After 24 and 52 Weeks of Treatment by
b-Blocker Use at Baseline (Full Analysis Set): Combined Data
Score
b-Blocker
(n ¼ 557)
No b-Blocker
(n ¼ 4,605)
Difference
(95% CI), L
Baseline
SGRQ total score, mean (SE) 43.58 (0.76) 43.60 (0.28) .
BDI focal score, mean (SE) 6.40 (0.09) 6.55 (0.03) .
24 wk
SGRQ total score, adjusted mean (SE) 36.36 (0.57) 37.75 (0.19) 1.39 (2.581 to 0.207)
TDI focal score, adjusted mean (SE) 1.61 (0.14) 1.79 (0.05) 0.18 (0.469 to 0.115)
52 wk
SGRQ total score, adjusted mean (SE) 37.29 (0.58) 37.90 (0.19) 0.60 (1.810 to 0.602)
TDI focal score, adjusted mean (SE) 1.57 (0.14) 1.70 (0.05) 0.13 (0.424 to 0.170)
BDI ¼ Baseline Dyspnea Index; SGRQ ¼ St. George’s Respiratory Questionnaire; TDI ¼ Transition Dyspnea Index.Patients using b-blockers at study entry experienced
fewer COPD exacerbations during the study than did
patients not using b-blockers (150 [26.9%] and 1,420
[30.8%], respectively). Time to ﬁrst COPD exacerbation
was not signiﬁcantly different between groups (271
vs 236 days for patients with and those without
b-blocker use, respectively; adjusted hazard ratio, 0.878;
95% CI, 0.732-1.053; P ¼ .1604) (Fig 2). Moderate or
severe exacerbations were experienced by 145 (26.0%)
and 1,339 (29.1%) patients with and those without
b-blocker use at study entry, respectively. There was no
difference in time to ﬁrst moderate or severe
exacerbation between groups: 304 vs 261 days for
patients with and those without b-blocker use at
baseline, respectively (adjusted hazard ratio, 0.896;
95% CI, 0.745-1.079; P ¼ .2471).
Analysis of Safety by Indication for b-Blockers
Approximately one-half of all patients in TONADO had
an indication for b-blocker treatment according to their
recorded cardiovascular disease at baseline:
tachyarrhythmias, including supraventricular and
ventricular tachyarrhythmias; ischemic heart disease,
including myocardial infarction and noninfarction; any
diagnosis of cardiac failure or heart failure New York
Heart Association class III or IV; or hypertension.
Within the b-blocker indication subgroup, the
demographic characteristics relating to preexisting
disease and concomitant medications of patients with
and those without b-blocker treatment were more
similar than in the total cohort. Age, sex, and smoking
history were similar in the b-blocker and no b-blocker
groups, and, as in the entire cohort, baseline FEV1 was
higher in patients receiving b-blockers than in those not
receiving them (e-Table 2).1320 Original ResearchWithin the b-blocker indication subgroup,
cardiovascular events (e-Table 3) and major adverse
cardiovascular events incidences were similar for
patients who were receiving b-blocker treatment (2.7%)
and those who were not (2.7%). The incidence of fatal
AEs was low across both groups: 1.9% in the b-blocker
group and 1.8% in the no b-blocker group. As in the
total cohort, in the b-blocker indication subgroup the
incidence of the majority of respiratory events was
numerically lower in patients receiving b-blockers than
in patients not receiving b-blockers (e-Table 3).Discussion
The TONADO studies offered a unique opportunity to
investigate the inﬂuence of b-blocker use on the safety
and efﬁcacy of long-acting bronchodilator treatment
with tiotropium/olodaterol. To our knowledge, this
study is also the ﬁrst to investigate whether b-blocker
use modiﬁes clinical responses to long-acting
bronchodilators by assessing well-deﬁned and relevant
patient-orientated end points such as dyspnea, quality of
life, and exacerbation frequency. In the TONADO
studies, in which lung function was improved
signiﬁcantly by use of long-acting bronchodilator
treatment, lung-function measures were similar between
patients receiving b-blocker treatment and those
without. In the b-blocker group, however, mean
postbronchodilator FEV1 at baseline was higher, and
there were more patients with GOLD II COPD and
fewer patients with GOLD III or IV compared with
those in the no b-blocker group. This result is consistent
with that observed in the COPDGene cohort and may
reﬂect a reluctance among physicians to use b-blockers
in patients with more severe COPD.18 Results of the[ 1 5 3 # 6 CHES T J U N E 2 0 1 8 ]
TABLE 5 ] Frequency of AEs, Serious AEs, and Fatal AEs After 52 Weeks of Treatment Occurring in > 2% of Patients
by b-Blocker Use at Baseline (Treated Set): Combined Data
Variable, No. (%) b-Blocker No b-Blocker
Total No. of patients 557 (100) 4,605 (100)
All AEs 412 (74.0) 3,428 (74.4)
Serious AEs 108 (19.4) 738 (16.0)
Respiratory, thoracic, and mediastinal disorders 30 (5.4) 331 (7.2)
COPD 24 (4.3) 282 (6.1)
Cardiac disorders 18 (3.2) 75 (1.6)
Infections and infestations 20 (3.6) 131 (2.8)
Neoplasms benign, malignant, and unspeciﬁed 16 (2.9) 99 (2.1)
Vascular disorders 13 (2.3) 22 (0.5)
Fatal AEs 11 (2.0) 64 (1.4)
Speciﬁc AEs with an incidence > 2%
Respiratory, thoracic, and mediastinal disorders 208 (37.3) 1,954 (42.4)
COPD exacerbation or worsening 158 (28.4) 1,537 (33.4)
Cough 21 (3.8) 184 (4.0)
Dyspnea 26 (4.7) 183 (4.0)
Infections and infestations 207 (37.2) 1,665 (36.2)
Nasopharyngitis 72 (12.9) 565 (12.3)
Urinary tract infection 23 (4.1) 83 (1.8)
Upper respiratory tract infection 24 (4.3) 273 (5.9)
Pneumonia 14 (2.5) 137 (3.0)
Bronchitis 16 (2.9) 122 (2.6)
Inﬂuenza 12 (2.2) 119 (2.6)
GI disorders 86 (15.4) 674 (14.6)
Diarrhea 16 (2.9) 120 (2.6)
Musculoskeletal and connective tissue disorders 91 (16.3) 580 (12.6)
Back pain 23 (4.1) 131 (2.8)
Arthralgia 13 (2.3) 59 (1.3)
Nervous system disorders 52 (9.3) 413 (9.0)
Headache 11 (2.0) 143 (3.1)
General disorders and administration site conditions 55 (9.9) 349 (7.6)
Chest pain 15 (2.7) 70 (1.5)
Edema peripheral 11 (2.0) 53 (1.2)
Vascular disorders 48 (8.6) 248 (5.4)
Hypertension 16 (2.9) 155 (3.4)
Cardiac disorders 48 (8.6) 232 (5.0)
Neoplasms benign, malignant, and unspeciﬁed 21 (3.8) 142 (3.1)
Percentages were calculated using the total number of patients in the b-blocker use groups at baseline divided by the treatment class as the
denominator. AE ¼ adverse event.present analysis did not show any negative effects of
b-blocker treatment, even in patients with severe COPD.
Our study adds to the current knowledge regarding the
use of b-blockers in patients with COPD by showing
that patient quality of life and dyspnea were not
impacted negatively by b-blocker use. At 24 weeks,chestjournal.orgSGRQ total score was also improved in both groups,
with similar ﬁndings for dyspnea, measured by using
the Transition Dyspnea Index. Overall, the AE
proﬁle was similar in both groups. Fewer patients in
the b-blocker group had respiratory AEs, including
fewer COPD events, than did those in the no b-blocker
group. Patients receiving b-blockers with less severe1321
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Figure 2 – Kaplan-Meier estimates of probability of COPD exacerbation across the 1-year study by b-blocker use at baseline (treated set), for combined
data. Hazard ratio of time to ﬁrst COPD exacerbation was calculated by using a Cox proportional hazards model adjusting for COPD treatment, sex,
age, BMI, race (Asian vs non-Asian), Global Initiative for Chronic Obstructive Lung Disease stage, cardiac disorders, hypertension, angiotensin-
converting enzyme inhibitors, angiotensin II antagonists, and lipid-modifying agents.COPD at baseline may have contributed to this
observation. As expected, cardiac disorder AEs had a
higher frequency in the b-blocker group, likely because
of more preexisting cardiac disease at baseline. Similarly,
the overall number of patients with serious AEs was
slightly higher in the b-blocker group, which may reﬂect
the higher proportion of patients with general
comorbidities in this group.
To explore this issue further, we performed a secondary
analysis that was restricted to patients who had a clinical
indication for the use of a b-blocker. Approximately
one-half of patients in the TONADO studies had an
existing indication for b-blockers, but only 20% of them
received a b-blocker, another possible reﬂection of the
tendency to avoid the use of b-blockers in patients with
COPD. We found that the differences in cardiac
disorder AEs and serious AEs between patients with
b-blockers and those without became smaller compared
with what was seen in the overall cohort. This ﬁnding
would support the contention that the differences in AEs
and serious AEs that were seen between those receiving
b-blockers and those who were not were likely driven by
individuals with better cardiovascular health in the no
b-blocker group. In the subgroup of patients with a
b-blocker indication, cardiovascular events and major
adverse cardiovascular events incidences between
patients who were receiving b-blocker treatment and1322 Original Researchthose who were not were similar. In this analysis,
b-blockers were not protective against cardiovascular
events in the indication subgroup. However, it is not
known from the available data whether the severity of
cardiovascular conditions between the patients receiving
b-blockers and those not receiving b-blockers was the
same. Also, we would not expect that hypertension, a
relatively mild cardiovascular disease and the most
frequent condition of the b-blocker indications in the
present study would have led to cardiovascular events in
the 1-year study follow-up.
Within the b-blocker indication subgroup, there was a
numerical advantage for patients in the b-blocker
treatment group in terms of respiratory events
compared with patients not receiving b-blockers. This
ﬁnding suggests that treatment with b-blockers does not
increase respiratory events in patients with COPD,
although this ﬁnding could be inﬂuenced by the better
lung function at baseline in the group of patients
receiving b-blockers.
The most frequent system organ class of serious AEs—
respiratory, thoracic, and mediastinal disorders—was
observed more frequently in the no b-blocker group
(7.2% compared with 5.4%). Correcting for differences
in baseline characteristics, the tendency to prolonged
time to ﬁrst COPD exacerbation in the b-blocker group[ 1 5 3 # 6 CHES T J U N E 2 0 1 8 ]
did not reach statistical signiﬁcance. However, this trend
is consistent with the results of a prospective follow-up
of the COPDGene cohort, which included 3,464
individuals with COPD GOLD II through IV, although
that analysis had a median follow-up of 2 years
compared with 1 year in our study and reported delayed
time to ﬁrst exacerbation in patients treated with a
b-blocker.18
Mortality was low and not substantially different
between groups. We did not see a negative pulmonary
consequence with respect to AEs for patients taking a
b-blocker in this vulnerable population of patients with
COPD.
A 2005 systematic review provided reassurance that the
use of selective b-blockers is generally safe in stable
COPD21 and that their use should not be withheld
routinely from patients with COPD. However, exposure
to b-blockers in the included studies was short (2 days to
16 weeks), and diagnosing COPD via administrative
databases is poorly validated and potentially
unreliable.22,23 A 2011 study suggested that b-blockers
reduce mortality in patients admitted to the hospital
with acute COPD exacerbations.24 Another retrospective
study of patients with ischemic heart disease, congestive
heart failure, or hypertension who were hospitalized for
an acute COPD exacerbation found no association
between b-blocker use, in-hospital mortality, 30-day
readmission, or initiation of mechanical ventilation.25
Similarly to patients in this study, the COPDGene
cohort led to the conclusion that b-blockers were safe
and associated with signiﬁcantly reduced total and
severe exacerbations, including in patients with severe
oxygen-dependent disease.18 This ﬁnding is in contrast
to those of a 2013 study involving patients with COPD
requiring oxygen, which concluded that b-blocker use
may increase mortality in these individuals.26
Nevertheless, most available evidence indicates that
b-blockers are generally safe in patients with COPD,27
with the possible exception of patients with GOLD IV
receiving oxygen therapy. There are compelling reasons
to use cardioselective b-blockers in patients with COPD
who also have heart failure or have had myocardial
infarction.2 Guidance from the GOLD strategy
document, which is based on many of these studies,
suggests that the beneﬁts of selective b-blocker use for
ischemic heart disease, heart failure, atrial ﬁbrillation,
and hypertension are larger than the potential risks
associated with treatment, even in patients with severe
COPD.28 Our data appear to support thechestjournal.orgrecommendation to continue the concomitant use of
b-blockers in these patients.
Although counterintuitive at ﬁrst glance, there is a
strong pharmacologic rationale to support the safety
and/or potential pulmonary beneﬁts of b-blocker
therapy in patients with COPD, particularly in the
presence of a concomitant chronic heart disease.29
Long-term adrenergic stimulation, related either to the
presence of a chronic disease or to long-term use of
b-agonists, is seen in COPD and eventually may down-
regulate the expression of b-adrenergic receptors and
attenuate the airway relaxation effects of b-agonists.29
These adverse consequences of long-term adrenergic
stimulation could be mitigated by the long-term use of
b-blockers30 through the reduction in sympathetic tone
and the upregulation of b-adrenoceptors in the
lungs.29,31 Irrespective of the exact underlying
pharmacologic mechanisms, a meta-analysis of 15
pooled cohort studies on the use of b-blockers in
patients with COPD suggested that b-blockers may
reduce the risk of overall mortality and exacerbation in
those patients.32
This analysis was across 12 months, compared with
previously reported, shorter-term data,21 and was
performed in patients who were well characterized with
thorough clinical monitoring of relevant outcomes.
b-Blocker use at baseline was a surrogate for use
throughout the study; however, adherence to b-blockers
was not monitored during the study. The analysis does
not have the strength of a prospective randomized
clinical trial, and the trial was not designed and
randomized to test for the effect of b-blocker use on
outcome measures. Therefore, baseline characteristics
showed some differences (eg, in COPD severity and
comorbidities), though analyses were controlled for
these differences in patient characteristics. However, the
large data set for this post hoc analysis from the
TONADO studies with a close follow-up provides
conﬁdence regarding the surveillance of COPD
exacerbations and AEs.
One limitation of these analyses is that patients with
myocardial infarction, hospitalization for heart failure in
the 12 months prior to screening, or unstable or life-
threatening cardiac arrhythmias were excluded from the
TONADO studies. However, the study included patients
with clinically signiﬁcant cardiac disease, including those
with cerebrovascular accidents, heart failure, and a
history of cardiac disorders according to the Medical
Dictionary for Regulatory Activities system organ class1323
deﬁnition available at www.meddra.org/. Furthermore,
the multicenter and international nature of the trial led
to a broad study population, adding further conﬁdence
to the application of these ﬁndings to clinical practice.
Some limitations could be circumvented by the ongoing
clinical trial evaluating the efﬁcacy of b-blockers to
prevent COPD exacerbation; however, all patients with
an indication for b-blocker treatment are excluded from
participation in this trial.33 Therefore, data about the
safety of b-blockers in this population are unlikely to
emerge from randomized studies. Although
confounding by indication is a potential caveat to the
validity of our results, all analyses (except safety
analyses) were performed after adjusting for important
baseline variables, including comorbid conditions.
Therefore, we are conﬁdent that this analysis provides1324 Original Researchimportant insights concerning the safety of b-blockers in
patients with COPD and adds to the evidence base for
their use in patients with COPD.Conclusions
Overall, there was no relevant effect of b-blocker use on
lung function, SGRQ score, or dyspnea in patients with
moderate to very severe COPD treated with tiotropium/
olodaterol in the TONADO studies. No increase in
respiratory AEs or exacerbations was observed in
patients receiving tiotropium/olodaterol and b-blockers.
Our ﬁndings are consistent with the guidance
supporting the continuation of usual maintenance
therapy in patients with COPD with b-blocker use when
clinically indicated.Acknowledgments
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